Welcome to our dedicated page for Bausch + Lomb news (Ticker: BLCO), a resource for investors and traders seeking the latest updates and insights on Bausch + Lomb stock.
Bausch + Lomb Corporation reports developments across its global eye health business, including vision care, surgical devices and ophthalmic pharmaceuticals. Recurring updates cover contact lenses and lens care products, eye vitamins and redness-relief drops, dry eye and prescription ophthalmology brands, intraocular lenses, vitrectomy cutters and the Stellaris Elite Vision Enhancement System.
Company news also includes financial results and guidance, scientific presentations, R&D pipeline discussions, FDA 510(k) clearances, European product launches and sustainability programs such as ONE by ONE Recycling. Product-specific coverage frequently references Biotrue, LUMIFY, XIIDRA, MIEBO, PreserVision, INFUSE, ULTRA ONE DAY, enVista and Bi-Blade technologies.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) has launched the ‘Screen, Protect, Cure’ campaign to raise awareness about glaucoma during Glaucoma Awareness Month. This initiative aims to educate at-risk individuals on the importance of early detection and treatment. The campaign features a fundraising challenge matching up to $20,000 for glaucoma research. Currently, about three million people in the U.S. are affected by this sight-threatening disease, highlighting the need for continued education and research in eye health.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) announced that CEO Joseph C. Papa will continue in his role until at least March 4, 2023, per an Amended Separation Agreement. The agreement allows for potential extensions until June 30, 2023, depending on the Board's discretion or the appointment of a successor. Changes to Papa's compensation were also noted. Bausch + Lomb is a global eye health leader with a portfolio exceeding 400 products, and it operates in nearly 100 countries. For more information, visit www.bausch.com.
Bausch + Lomb (NYSE: BLCO) has received FDA 510(k) clearance for its Biotrue Hydration Boost Contact Lens Rehydrating drops. This preservative-free product is designed for soft and rigid gas permeable lenses, providing up to eight hours of moisture. With one-third of the 45 million U.S. contact lens wearers experiencing dryness, this product is expected to cater to a significant market need. The drops contain hyaluronan and match the pH of healthy tears, enhancing user comfort. Availability is anticipated in the first half of 2023.
Bausch + Lomb (NYSE/TSX: BLCO) announced its ONE by ONE and Biotrue Eye Care Recycling programs have won the gold award for 'Most Environmentally Friendly Service of the Year' at the 2022 Best in Biz Awards. Joe Gordon, president of Global Consumer, emphasized the company's commitment to sustainability, highlighting progress in recycling over 60 million used contact lenses and eye care materials. These programs aim to address plastic pollution by enabling the proper recycling of items typically not accepted in standard facilities.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) announced that its new contact lens solution, Biotrue Hydration Plus, has won the 2022 BIG Awards for Business Product of the Year from Business Intelligence Group. This innovative solution enhances moisture retention for contact lens wearers, providing all-day comfort and exceptional disinfection with a triple disinfectant system. It incorporates bio-inspired ingredients, including 25% more hyaluronan, potassium, and erythritol, to match the pH of healthy tears, addressing the needs of patients suffering from contact lens dryness.
Bausch + Lomb (NYSE/TSX: BLCO) has announced that its innovative recycling programs, ONE by ONE and Biotrue Eye Care, have successfully collected over 58 million units (approximately 356,723 pounds) of used contact lenses and related materials since their inception. This effort, in collaboration with TerraCycle, helps reduce environmental pollution caused by non-biodegradable plastics in the U.S. The ONE by ONE program has been active since November 2016, while the Biotrue program began in April 2021. These initiatives highlight Bausch + Lomb's commitment to sustainability.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) will participate in the 5th Annual Evercore ISI HealthCONx Conference on November 30, 2022, at 9:40 a.m. ET. The event will feature CEO Joseph C. Papa and CFO Sam Eldessouky. A webcast of the presentation will be available on the company's Investor Relations page.
Founded in 1853, Bausch + Lomb is a global leader in eye health, offering over 400 products, including contact lenses and ophthalmic pharmaceuticals. The company is headquartered in Vaughan, Ontario, with a significant global presence.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) reported third-quarter 2022 revenues of $942 million, a 1% decline year-over-year, impacted by $55 million in foreign exchange losses. Adjusted EBITDA was $187 million, down from $207 million in 2021. The net loss attributable to the company was $18 million, compared to a net income of $60 million the previous year. Despite challenges, organic revenue grew 5%, driven by strong performance in all segments. The company revised its full-year 2022 guidance due to currency headwinds, with revised revenues expected between $3.70 billion and $3.75 billion.
Summary not available.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) has launched Project Watson, a new line of health care products for dogs in the U.S., aimed at enhancing their eye, ear, and overall wellbeing. Developed in collaboration with veterinarians, products include eye wash, eyelid wipes, ear wash, ear wipes, and health supplements targeting eye health and general health. The rollout begins in November 2022 at major retailers like Chewy and Walmart, contributing to Bausch + Lomb's longstanding commitment to pet care and addressing unmet health needs in pets.